Etrasimod: the ownership history and trial design both matter
Etrasimod, formerly APD334 and marketed as Velsipity, is an oral sphingosine-1-phosphate receptor modulator.
Etrasimod, formerly APD334 and marketed as Velsipity, is an oral sphingosine-1-phosphate receptor modulator. FDA approved it for adults with moderately to severely active ulcerative colitis in October 2023. Pfizer acquired Arena in March 2022, so records bearing either company's name belong to the same compound history. FDA approval snapshot, ownership account (below).
ELEVATE UC 52 assessed clinical remission at weeks 12 and 52, while the separate ELEVATE UC 12 trial assessed the shorter induction period. Both compared daily oral etrasimod with placebo. The 52-week treat-through design differs from programs that rerandomize only induction responders into maintenance; its later remission percentage should not be placed beside responder-enriched maintenance results without that explanation. ELEVATE UC 52, ELEVATE UC 12.
FDA's assessment supports benefit versus placebo, but an oral route does not by itself establish a more favorable safety profile. The drug's specific precautions and patient-selection requirements remain relevant. This overview does not use cross-trial percentages to choose a winner among oral therapies or biologics.
Pfizer's dated financial account (below) separates unrestricted cash, investments and debt. Arena's acquisition value covered a portfolio; it is not a disclosed etrasimod research budget. A future update should identify a substantive clinical, regulatory or ownership change. No specific next UC milestone is verified by the sources reviewed through September 22, 2026.
Pfizer — company resources
At June 28, Pfizer reported $0.976 billion of cash and equivalents plus $10.723 billion of short-term investments. Short-term debt, including current maturities, was $2.699 billion, with $60.495 billion of long-term debt. First-half operating cash flow was $3.450 billion. The cash-flow statement's ending cash figure includes restricted cash and is therefore not interchangeable with the unrestricted balance-sheet figure. These corporate resources provide context for etrasimod's owner without assigning a share of them to the medicine. Danuglipron was discontinued; current group liquidity does not imply renewed funding for that program. Form 10-Q filed August 4.
Pfizer and Arena — acquisition and etrasimod
Pfizer completed its acquisition of Arena in March 2022, before the FDA approved etrasimod for ulcerative colitis in October 2023. The acquisition covered Arena's broader portfolio, so its approximately $6.7 billion equity value is not a price or development budget for etrasimod alone. Trial records using Arena's name belong in the same compound history as subsequent Pfizer development and commercialization. Pfizer acquisition completion, FDA approval snapshot.
About this account
Published September 23, 2026. Company and regulatory disclosures are covered through September 22; trial-registry records were retrieved September 23. Earlier developments are reconstructed from dated primary sources. Registry status, sponsor-reported results and regulatory decisions are distinguished in the account. Company figures retain their reporting periods; corporate cash is not a compound-specific funding commitment.